Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer
ObjectiveBoennuokang® leuprorelin acetate microspheres show a certain efficacy in patients with prostate cancer, but its utilization as neoadjuvant therapy in patients with high-risk prostate cancer remains unclear. Hence, this real-world study investigated the efficacy and safety of Boennuokang® le...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1520370/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849771402402463744 |
|---|---|
| author | Changde Fu Jun Xin Jinjin Lai Xu Zeng Yongnan Wang Wei Zhang |
| author_facet | Changde Fu Jun Xin Jinjin Lai Xu Zeng Yongnan Wang Wei Zhang |
| author_sort | Changde Fu |
| collection | DOAJ |
| description | ObjectiveBoennuokang® leuprorelin acetate microspheres show a certain efficacy in patients with prostate cancer, but its utilization as neoadjuvant therapy in patients with high-risk prostate cancer remains unclear. Hence, this real-world study investigated the efficacy and safety of Boennuokang® leuprorelin acetate microspheres-based treatment as neoadjuvant therapy in patients with high-risk prostate cancer.MethodsThis retrospective study included 53 patients with high-risk prostate cancer who received Boennuokang® leuprorelin acetate microspheres as neoadjuvant therapy and laparoscopic radical prostatectomy.ResultsThe median prostate-specific antigen (PSA) was 34.1 ng/mL before neoadjuvant therapy and reduced to 0.8 ng/mL after neoadjuvant therapy (P<0.001). Testosterone showed a decreased tendency after neoadjuvant therapy, but without statistical significance (P=0.185). After surgery, 36 (67.9%) patients had negative surgical margin. The median (interquartile range) prostate volume reduced from 40.5 (33.4-55.2) mL before neoadjuvant therapy to 30.2 (25.2-40.2) mL after neoadjuvant therapy (P<0.001). Meanwhile, alkaline phosphatase before neoadjuvant therapy, at one month (M1), 3 months (M3), 6 months (M6), and 12 months (M12) after surgery tended to be increased (P=0.029), but this increment lacks clinical significance, while the glomerular filtration rate (P=0.441) and albumin (P=0.548) did not vary among different time points. Erectile dysfunction and loss of libido was the most common adverse event, with incidences of 84.9% during neoadjuvant therapy, 79.2% at M1, 71.7% at M3, 67.9% at M6, and 56.6% at M12.ConclusionBoennuokang® leuprorelin acetate microspheres-based treatment as neoadjuvant therapy decreases PSA, testosterone, and prostate volume, with acceptable positive surgical margin rate in patients with high-risk prostate cancer and its safety profiles should be validated. |
| format | Article |
| id | doaj-art-3438d3d10f7b4abf90cb8a7a42a5042a |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-3438d3d10f7b4abf90cb8a7a42a5042a2025-08-20T03:02:37ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-03-011510.3389/fonc.2025.15203701520370Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancerChangde FuJun XinJinjin LaiXu ZengYongnan WangWei ZhangObjectiveBoennuokang® leuprorelin acetate microspheres show a certain efficacy in patients with prostate cancer, but its utilization as neoadjuvant therapy in patients with high-risk prostate cancer remains unclear. Hence, this real-world study investigated the efficacy and safety of Boennuokang® leuprorelin acetate microspheres-based treatment as neoadjuvant therapy in patients with high-risk prostate cancer.MethodsThis retrospective study included 53 patients with high-risk prostate cancer who received Boennuokang® leuprorelin acetate microspheres as neoadjuvant therapy and laparoscopic radical prostatectomy.ResultsThe median prostate-specific antigen (PSA) was 34.1 ng/mL before neoadjuvant therapy and reduced to 0.8 ng/mL after neoadjuvant therapy (P<0.001). Testosterone showed a decreased tendency after neoadjuvant therapy, but without statistical significance (P=0.185). After surgery, 36 (67.9%) patients had negative surgical margin. The median (interquartile range) prostate volume reduced from 40.5 (33.4-55.2) mL before neoadjuvant therapy to 30.2 (25.2-40.2) mL after neoadjuvant therapy (P<0.001). Meanwhile, alkaline phosphatase before neoadjuvant therapy, at one month (M1), 3 months (M3), 6 months (M6), and 12 months (M12) after surgery tended to be increased (P=0.029), but this increment lacks clinical significance, while the glomerular filtration rate (P=0.441) and albumin (P=0.548) did not vary among different time points. Erectile dysfunction and loss of libido was the most common adverse event, with incidences of 84.9% during neoadjuvant therapy, 79.2% at M1, 71.7% at M3, 67.9% at M6, and 56.6% at M12.ConclusionBoennuokang® leuprorelin acetate microspheres-based treatment as neoadjuvant therapy decreases PSA, testosterone, and prostate volume, with acceptable positive surgical margin rate in patients with high-risk prostate cancer and its safety profiles should be validated.https://www.frontiersin.org/articles/10.3389/fonc.2025.1520370/fullleuprorelinhigh-risk prostatic cancerneoadjuvant therapyprostate-specific antigentestosterone |
| spellingShingle | Changde Fu Jun Xin Jinjin Lai Xu Zeng Yongnan Wang Wei Zhang Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer Frontiers in Oncology leuprorelin high-risk prostatic cancer neoadjuvant therapy prostate-specific antigen testosterone |
| title | Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer |
| title_full | Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer |
| title_fullStr | Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer |
| title_full_unstemmed | Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer |
| title_short | Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer |
| title_sort | real world analysis of leuprorelin acetate microspheres based neoadjuvant therapy for patients with high risk prostate cancer |
| topic | leuprorelin high-risk prostatic cancer neoadjuvant therapy prostate-specific antigen testosterone |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1520370/full |
| work_keys_str_mv | AT changdefu realworldanalysisofleuprorelinacetatemicrospheresbasedneoadjuvanttherapyforpatientswithhighriskprostatecancer AT junxin realworldanalysisofleuprorelinacetatemicrospheresbasedneoadjuvanttherapyforpatientswithhighriskprostatecancer AT jinjinlai realworldanalysisofleuprorelinacetatemicrospheresbasedneoadjuvanttherapyforpatientswithhighriskprostatecancer AT xuzeng realworldanalysisofleuprorelinacetatemicrospheresbasedneoadjuvanttherapyforpatientswithhighriskprostatecancer AT yongnanwang realworldanalysisofleuprorelinacetatemicrospheresbasedneoadjuvanttherapyforpatientswithhighriskprostatecancer AT weizhang realworldanalysisofleuprorelinacetatemicrospheresbasedneoadjuvanttherapyforpatientswithhighriskprostatecancer |